MedTrace Logo

Targeted T-cell Therapy in Solid Tumors

NCT04076137 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-09-03

No results posted yet for this study

Summary

This is a single-center, open, single-arm controlled prospective clinical trial of patients with solid tumors treated with targeted activation of T cells through intravenous infusion.The purpose of this study was to evaluate the clinical efficacy and safety of targeted activated T cells in the treatment of solid tumors.

Conditions

  • Malignant Solid Tumor

Interventions

OTHER

Targeted T-cell armed with bispecific antibody (Decitabine)

In this study, 10 patients eligible for the study were clinically screened for intravenous infusion of targeted activated T cells,every participant has a unique identification number and emergency letter which have the information of group.

Sponsors & Collaborators

  • Shenzhen Second People's Hospital

    collaborator OTHER

  • Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zeqiang Zhou, Doctor · Department of oncology, the second people's hospital of shenzhen

  • Wenli Liang, Doctor · Department of oncology, the second people's hospital of shenzhen

  • Liang Xiao, Doctor · Department of oncology, the second people's hospital of shenzhen

  • Lin Lin, Doctor · Department of oncology, the second people's hospital of shenzhen

  • Meixiang Li, Doctor · Department of oncology, the second people's hospital of shenzhen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-05-01
Completion
2021-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04076137 on ClinicalTrials.gov